Evaluation of Health-Related Quality of Life in Patients Treated with RBX2660 (microbiota suspension) for Recurrent C. difficile Infection

Bharat Misra, MD, Borland-Groover Clinic, Jacksonville, FL; Mayur S. Ramesh, MD, Henry Ford Health System, Detroit, MI; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc, Roseville, MN

Evaluation of Health-Related Quality of Life in Patients Treated with RBX2660 (microbiota suspension) for Recurrent C. difficile Infection

Download this poster (108 KB)
Download the abstract (339 KB)

American College of Gastroenterology
October 8-12, 2014, Philadelphia, PA

Purpose

Recurrent C. difficile infection is a debilitating condition known to have major effects on  both patient physical and mental health. Little is known about the quality of life aspects of this chronic condition.  We report on changes in health-related quality of life (HRQOL) as assessed with the Short Form 36 (SF-36) in patients enrolled in the PUNCH CD phase 2 safety assessment of RBX2660 (microbiota suspension) for recurrent C. difficile infection.